Biotech M&A Trends With Allan Shaw
Business Of Biotech
00:00
Accelerating Therapeutic Discovery
I think our attributes have really been very therapeutically focused. You know, if you're starting a phase three study by yourself, why isn't anyone working with you? I would also call out Loxo oncology when they were trading around $3 billion market cap reasonably could market cap where they were relative to development. They wound up collaborating that lead program with bear basically effectively out licensed a lot of it got a great deal. But it was disappointing because people it took the M&A buzz out of the stock,. The company at the time, their CEO Josh, he saw a lot more value in the platform in the portfolio. That was not being subscribed to. It's
Transcript
Play full episode
